LifeMine Therapeutics is identifying drugs through mining genetically-encoded small molecules (GEMs) from the biosphere. Solutions to medical problems may have already been solved by nature. This is the rationale LifeMine has taken to digitally search for new drugs in natural biological space. Using their Avatar-Rx platform, LifeMine integrates high-throughput microbiology, machine learning and genome engineering to search the fungal biosphere for novel GEMs that bind human targets. Candidates are then optimized using state-of-the art chemical synthesis to advance new products into development. LifeMine has already announced a strategic R&D collaboration with GlaxoSmithKline for multiple disease areas.

<p>LifeMine Therapeutics is identifying drugs through mining genetically-encoded small molecules (GEMs) from the biosphere. Solutions to medical problems may have already been solved by nature. This is the rationale LifeMine has taken to digitally search for new drugs in natural biological space. Using their Avatar-Rx platform, LifeMine integrates high-throughput microbiology, machine learning and genome engineering to search the fungal biosphere for novel GEMs that bind human targets. Candidates are then optimized using state-of-the art chemical synthesis to advance new products into development. LifeMine has already announced a strategic R&amp;D collaboration with GlaxoSmithKline for multiple disease areas.</p>


LifeMine Therapeutics

We are excited to announce that David Surguladze, MD, has joined LifeMine Therapeutics as Vice President, Head of Non-Clinical Development. With 27 years of distinguished experience in drug development, Dr. Surguladze will spearhead our preclinical development strategy, enhancing our efforts to deliver innovative medicines to patients in dire need of new treatments. We are confident in his expertise and leadership to guide our high-value pipeline projects towards success. Welcome to the team, David! We look forward to achieving remarkable milestones together in our journey to bring sophisticated medicines to patients in urgent need of breakthrough disease intervention.

“When do you ever see a fundamentally new way of discovering drugs? That’s what we’re dealing with." At LifeMine, we are the first company that was founded to discover powerful next-generation medicines that were evolved in nature, taking a bold new approach that leverages evolutionary insights from fungi to unearth sophisticated medicines for patients in urgent need of breakthrough disease intervention. 

This is the next wave of new medicines. This is Top-Down Drug Discovery™. This is LifeMine. Our Co-Founder and CEO, Greg Verdine, shares more below.

 Finalists Unveiled for 2023 BWB Awards: Biotech Week ... 

LifeMine Therapeutics Appoints Elliot Ehrich, M.D., as Chief Medical Officer and EVP of Translational Science and Lata Jayaraman, Ph.D., as EVP and Head of Biology - Business Wire

As the LifeMine team advances next-generation therapeutics at scale, we continue to build an elite team of experts. We’re honored to welcome Chong-Hui Gu, Ph.D., as SVP, Head of CMC and Sam Tran as VP of Information Technology.

Dr. Chong-Hui Gu is a distinguished leader in #drugdiscovery and development, with over 24 years of experience driving progress in therapeutic programs and contributing to the success of multiple FDA-approved drugs. Samuel brings extensive experience across private and public companies, leading initiatives in cybersecurity, IT, software engineering, and more. 

Both will play a critical role in LifeMine’s evolution as we translate advancements in human genetics into the next wave of new medicines with unprecedented actionability, predictability and scalability. 

https://doi.org/10.1021/acs.jmedchem.4c01095

 LifeMine Therapeutics Expands Management Team with Appointments of Martin Stahl, Ph.D., as Chief Scientific Officer and Louis Plamondon, Ph.D., as Executive Vice President and Head of CMC 

 LifeMine Therapeutics and GSK Enter Drug Discovery and Development Alliance 

Greg Verdine's newest startup bags $55M to create drugs out of fungi - The Business Journals

Biotech Firms Lease More Than Half the Space at 66 Galen in Watertown - Connect CRE

 Greg Verdine on LinkedIn: #JPM24: Greg Verdine's LifeMine eyes the clinic next year with T-cell… 

LifeMine Therapeutics appoints Martin Stahl and Louis Plamondon as executives - MM+M Online

For biotech entrepreneur Greg Verdine, opportunity just kept knocking - The Business Journals

 Deep Learning Methods For Biosynthetic Gene Cluster Discovery 

Genomic Discovery and Structure–Activity Exploration of a Novel Family of Enzyme-Activated Covalent Cyclin-Dependent Kinase InhibitorsJournal of Medicinal ChemistrySeptember 26, 2024Publications

People - Nature.com

Greg Verdine, Bio + Health Venture Partner - Andreessen Horowitz

 LifeMine Therapeutics Announces $175 Million Series C Financing 

Entrepreneurs: WeiQing Zhou - PharmaVoice

LifeMine Therapeutics combines AI, drug discovery & microbes with $55m launch - Drug Delivery Business

This month, we come together to celebrate Pride and honor the diverse and vibrant LGBTQIA+ community within our workplace and beyond. At LifeMine, we believe in fostering an environment of belonging where everyone feels valued and respected.
 
To celebrate Pride Month, we hosted a Paint & Sip event at our Cambridge location. It was a wonderful opportunity for LifeMiners to express their creativity and celebrate our commitment to diversity and inclusion.
 
We're proud to support and stand with our LGBTQIA+ colleagues and friends, not just during Pride Month, but every day of the year. Together, we're building a workplace where everyone can thrive.
 
Check out some of the amazing artwork from our Paint & Sip event below! 

Evecxia Therapeutics Strengthens Board of Directors With Appointments of Allan L. Shaw and Elliot Ehrich - Business Wire

Genomic Discovery and Structure–Activity Exploration of a Novel Family of Enzyme-Activated Covalent Cyclin-Dependent Kinase Inhibitors | Journal of Medicinal Chemistry - ACS Publications

 Lihua Yu on LinkedIn: A personal update I have started a new role in LifeMine Therapeutics… | 34 comments 

Fierce Biotech's 2022 Fierce 15 - Fierce Biotech

LifeMine Therapeutics Announces $50 Million Series B Financing - Business Wire

LifeMine Therapeutics Expands Management Team with Appointments of Martin Stahl, Ph.D., as Chief Scientific Officer and Louis Plamondon, Ph.D., as Executive Vice President and Head of CMC - Business Wire

We are excited to share a recent publication in the Journal of Medicinal Chemistry that underscores the power of our data-immersive, genomics-enabled drug discovery engine of LifeMine.

Through our Top-Down Drug Discovery™ approach, we have identified a novel family of enzyme-activated covalent CDK inhibitors. This represents the first example in which fungal genetically encoded molecules (GEMs) inhibiting a human protein of therapeutic interest were discovered first by a targeted search in genomic space. These molecules exhibit a remarkable and differentiated mechanism, forming a site-selective covalent bond to a specific CDK active site.

This work truly highlights the ability of Top-Down Drug Discovery™ to identify mechanistically and structurally novel molecules for the development of new medicines. Congratulations to all our talented LifeMiners involved in this important work!

Read more here in ACS Publications: https://lnkd.in/eYBdCd56 

 [Video] Greg Verdine on LinkedIn: LifeMine Therapeutics has been operating in Basel for more than a year… 

Serial biotech entrepreneur Greg Verdine joins Andreessen Horowitz - The Business Journals

LifeMine Announces First Participant Dosed in First-in-human Phase 1 Clinical Trial of LIFE-001, Designed De Novo to Become a Field Dominating Immunosuppressive for Immune-mediated Disorders and Transplantation - Business Wire

A former Harvard chemist just raised $178 million for a biotech startup that plans to treat previously untreatable cancers - Business Insider

LifeMine locks down $70M 'dream scenario' fungi partnership with GSK—and a fundraising, too - Fierce Biotech

Harvard Biotech Guru, VCs Launch LifeMine With $55 Million Series A - BioSpace

Fungal genomes scoured for drugs - Nature.com

LifeMine and GSK sign partnership for small molecule leads - Pharmaceutical Technology

GSK partners with LifeMine as startups advance plans to make drugs from fungi - BioPharma Dive

Davis and Boston Development Group secure 117,645 s/f in leases at 66 Galen St. - New England Real Estate Journal Online

3 biotech executives on the year ahead: deals, drug pricing and the down market - BioPharma Dive

LifeMine Therapeutics doses first subject in Phase I trial of LIFE-001 - Yahoo

LifeMine Therapeutics doses first subject in Phase I trial of LIFE-001 - Clinical Trials Arena

 Greg Verdine took a long route to be a biotech entrepreneur ... 

 Methods and systems for discovery of embedded target genes in biosynthetic gene … 

LifeMine Tx appoints CSO and exec VP of CMC - The Pharma Letter

 LifeMine’s restructuring; Europe won’t renew authorization for PTC’s Duchenne drug 

 Compounds, compositions, and methods of treatment thereof 

LifeMine Therapeutics lays off staff, reprioritizes to drill lead asset into clinic - Fierce Biotech

 Computational Method To Identify Gene Networks Containing Functionally-Related … 

 Greg Verdine took a long route to be a biotech entrepreneur and Harvard professor - Boston Business Journal 

Life-Saving Drugs Hiding in Plain Sight: LifeMine Therapeutics CEO Greg Verdine, Live at NYSE - Yahoo Finance

 Methods and systems for discovery of non-embedded target genes 

2 Life Science Companies Sign Leases at Galen Street Building - Watertown News

 LifeMine Therapeutics Appoints Jennifer A. Jarrett to Board of Directors 

Greg Verdine’s LifeMine eyes the clinic next year with T-cell immunosuppressive and antifungal: #JPM24 - Endpoints News

LifeMine Therapeutics Announces $175 Million Series C Financing - Business Wire

 Anna Lechner on LinkedIn: Passionate about exactly this concept and one of many reason for working… 

 Life-Saving Drugs Hiding in Plain Sight: LifeMine Therapeutics CEO Greg Verdine, Live at NYSE 

LifeMine Therapeutics Appoints Jennifer A. Jarrett to Board of Directors

Finding new therapeutics in fungi - Knovel

 Methods and systems for identifying genes associated with biosynthetic gene … 

Greg Verdine - Andreessen Horowitz

LifeMine locks down $70M 'dream scenario' fungi ...

 Methods and Systems for Discovery of Embedded Target Genes in Biosynthetic Gene … 

 Stacey Hero on LinkedIn: Already learning a ton and enjoying being a part of this incredible team! | 40 comments 

 Deep learning methods for biosynthetic gene cluster discovery 

Why a top Roche scientist is leaving after 25 years to join a rising biotech startup using fungi to make new drugs - Business Insider

 The Week’s 10 Biggest Funding Rounds: Yuga Labs Goes Ape For A Large Round, Fintech Rules Again 

LifeMine raises $175m to find drugs from fungi - The Boston Globe

Top-Down Drug Discovery™ is made possible by our data-immersive Avatar-Rx™ platform, which provides the ability to deep-mine fungal genomes for transformational precision medicines across different disease areas. This way, we're positioned to translate advancements in human genetics into the next wave of new medicines with unprecedented actionability, predictability and scalability.
	
Learn more about Avatar-Rx™ and LifeMine's approach below and at	 	www.LifemineTx.com

At LifeMine, recognizing Pride Month is about more than celebrating the LGBTQIA+ community; it’s about embracing diversity, promoting inclusion and belonging, and continuing to stand up for equality. Our Core DNA exemplifies our pursuit to learn through growth and curiosity within the lab and outside of it. By learning more about each other, we contribute to a more understanding and accepting culture for everyone. Happy #PrideMonth2024!

 LifeMine Therapeutics Expands Management Team with Appoin... 

LifeMine Announces First Participant Dosed in First-in-human Phase 1 Clinical Trial of LIFE-001, Designed De Novo to Become a Field Dominating Immunosuppressive for Immune-mediated Disorders and TransplantationApril 8, 2025Press Releases

We’re thrilled to unveil our brand new look at lifeminetx.com. Our new website invites you into the world of LifeMine to explore our pioneering Top-Down Drug Discovery™ approach that leverages evolutionary insights from fungi to unearth next generation #precisionmedicines. Learn about our transformative platform, Avatar-Rx™, powerful programs and pipeline, and our remarkable team who embodies our expedition culture, driving our mission to bring sophisticated medicines to patients in urgent need.

Check out the video below for a glimpse into our new virtual home, and visit our website to find out more.

 Computational method to identify gene networks containing functionally-related … 

Chutes & Ladders—3 Flagship-backed biotechs make key exec hires - Fierce Biotech

LifeMine Therapeutics, GSK Ink $70M Drug Discovery, Development Pact - Yahoo Finance

LifeMine Therapeutics and GSK Enter Drug Discovery and Development Alliance - Business Wire

Rick Klausner fronts cash for his fungus outfit LifeMine and brings on Nobel laureate to further push cancer discovery - Endpoints News

LifeMine Therapeutics Appoints Elliot Ehrich, M.D., as Chief Medical Officer and EVP of Translational Science and Lata Jayaraman, Ph.D., as EVP and Head of Biology

GSK joins LifeMine’s $175M funding, reviving fungi as a drug discovery frontier - MedCity News

Top-Down Drug Discovery™ prioritizes a molecule’s function, versus its chemical structure, to identify pharmacologically privileged drugs to engage therapeutic targets in novel ways. LifeMine has the ability to significantly improve the speed of drug discovery comparable to the standard practice of “bottom-up” discovery which includes many complex, time-consuming steps, and is often labor and resource intensive, therefore unscalable to meet the demands of the future.
 
We’re in uncharted territory, discovering and developing novel precision medicines against high-impact disease targets – including those previously deemed undruggable – with unprecedented speed, predictability, and scalability. 
 
Discover more from our Co-Founder and CEO, Greg Verdine, below.

LifeMine Therapeutics Powers Drug Discovery Team to Search the Biosphere for Nature's Evolved Solutions to Intractable Therapeutic Challenges - BioSpace

 Methods And Systems For Discovery Of Non-Embedded Target Genes 

 The genome of antibiotic-producing colonies of the ... 

LifeMine is making excellent progress as we seek to reimagine drug discovery and bring sophisticated, next-generation medicines to patients in urgent need. As we continue to evolve, we are thrilled to welcome Simon Cooper as our chief medical officer. Dr. Cooper brings an extensive background in translational medicine and clinical development, as well as a demonstrated track record working across multiple modalities in both pharmaceutical and biotech companies. He is exceptionally well-positioned to lead the continued advancement of our pipeline.

We would also like to express our sincere gratitude to Elliot Ehrich, MD for his transformative contributions to LifeMine, especially his pivotal role in conceptualizing our CNi program and advancing our lead program LIFE-001. Dr. Ehrich will transition to the role of Clinical and Scientific Advisor. We are incredibly fortunate to have these two fantastic leaders on our team. 

We are thrilled to share that the first participant has been dosed in a first-in-human Phase 1 clinical trial evaluating LIFE-001, a structurally and mechanistically novel calcineurin inhibitor (CNi) being developed for multiple immune-mediated disease indications and organ transplant rejection. In preclinical studies, LIFE-001 has demonstrated radically improved safety compared to legacy CNis, improved convenience of drug administration, and compelling efficacy in validated animal models of ulcerative colitis and crohns disease. Our clinical molecule LIFE-001 is designed de novo to become a field dominating immunosuppressive for immune-mediated disorders.

LifeMine’s transition into a clinical-stage company marks a significant achievement for our dedicated team and underscores the power of our genomic discovery engine to bring sophisticated medicines to patients in urgent need of breakthrough disease intervention.

Discover more about LIFE-001 and the Phase 1 trial: https://lnkd.in/ee8PQ6qE

 LifeMine Therapeutics lays off staff, reprioritizes to drill lead asset into clinic 

We're unearthing something new at LifeMine... Stay tuned for more updates and check out a sneak peek for what's in store below. 

Amid lab space glut, a big lease at last - The Boston Globe

LifeMine Therapeutics Expands Management Team with Appointments of Martin Stahl, Ph.D., as Chief Scientific Officer and Louis Plamondon, Ph.D., as Executive Vice President and Head of CMC

LifeMine Therapeutics

Business:

Drug notes:

About: